Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy GlobeNewswire - Tue Jan 6, 6:00AM CST

Data demonstrate  clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding...

MCRB : 15.86 (+1.99%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference GlobeNewswire - Mon Nov 24, 2025

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat...

MCRB : 15.86 (+1.99%)
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Wed Nov 5, 2025

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant...

MCRB : 15.86 (+1.99%)
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 GlobeNewswire - Thu Oct 30, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and...

MCRB : 15.86 (+1.99%)
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 GlobeNewswire - Wed Oct 29, 2025

CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria...

MCRB : 15.86 (+1.99%)
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant GlobeNewswire - Tue Oct 14, 2025

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from...

MCRB : 15.86 (+1.99%)
Seres Therapeutics Cuts Costs to Extend Cash Runway Tipranks - Sat Oct 4, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Seres Therapeutics...

MCRB : 15.86 (+1.99%)
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway GlobeNewswire - Tue Sep 23, 2025

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell...

MCRB : 15.86 (+1.99%)
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Wed Aug 27, 2025

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright...

MCRB : 15.86 (+1.99%)
Seres Therapeutics: Q2 Earnings Snapshot AP - Wed Aug 6, 2025

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 15.86 (+1.99%)

Barchart Exclusives

This Dividend Stock Gained 66% Last Year. Is The 2026 Forecast as Bright? Barchart - 1 hour ago
Citigroup shares gained almost 65% last year and outperformed large-cap banking peers. However, after the rally, Citi's dividend yield is now comparable to peers, and the valuations look fair, making the risk-reward quite balanced. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot